Altogether, the findings of this study suggest that modulating microbiota–BA–FXR/TGR5 signaling pathway may be a potential mechanism of action of LGZG oral solution for the treatment of MASLD. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.